DSM Launches InnoSynTM Route Scouting Services to Meet Pharmaceutical Company Needs to Outsource R&D

DSM Launches InnoSynTM Route Scouting Services to Meet Pharmaceutical Company Needs to Outsource R&D
 
PARSIPPANY, N.J., Sept. 7 /PRNewswire/ -- DSM Pharma Chemicals, a business unit of DSM Pharmaceutical Products, today announced the launch of InnoSynTM route scouting services. In response to the increasing interest of pharmaceutical customers to outsource the development of robust low-cost manufacturing routes, DSM is offering focused and flexible stand alone route scouting services.  DSM's route scouting capabilities lead to significant cost savings by the reduction of synthesis steps or redesign of synthesis routes.

The InnoSynTM route scouting team supports research and development, and the implementation of economical and scalable routes. Unique value creating solutions are provided by integrating the full range of enabling DSM competencies such as biocatalysis, homogeneous catalysis, organic synthesis and continuous chemistry using for example micro reactors. These capabilities to rapidly screen a wide variety of catalysts speed up feasibility studies for chemocatalytic and biocatalytic steps.

Recent success stories have introduced new efficient enzymes, such as pharmaPLE®, lyases, transaminases, dehydrogenases and new, easily accessible homogeneous catalysts for asymmetric hydrogenations, aromatic substitutions, and oxidations. Furthermore, a safe and clean nitration reaction was implemented under cGMP for manufacturing of an API based on DSM's micro reactor technology.  InnoSynTMservices are based in DSM's Geleen, The Netherlands R&D facilities and utilize DSM's wide range of technology and production sites across Europe.

Oliver May, Ph.D., Business Manager InnoSynTM route scouting services commented, "DSM is recognized as a reliable and leading large scale cGMP manufacturer for registered intermediates and active pharmaceutical ingredients. This remains our focus but we also want to continuously serve changing customer needs whenever DSM can provide real value. Due to the reduced focus and resources in process R&D within our customers' operations there is an increasing demand for developing flexible and robust 'technology packages' ready to implement at large scale. The new DSM InnoSynTM route scouting services are setup to address exactly this specific need based on DSM's broad and unique technology toolbox. Please visit us at CPhI Worldwide Oct 5-7 in Paris to learn more about the value we provide in this area." 

Dr. May will be speaking at 13:00 PM on Tuesday, October 5th at the global CPhI Worldwide conference in Paris.

InnoSynTM is a trademark of DSM

pharmaPLE® is a registered trademark of DSM

DSM Pharma Chemicals

DSM Pharma Chemicals is a global provider of custom manufacturing services to the pharmaceutical industry, including advanced intermediates, registered materials and active pharmaceutical ingredients. Our offerings include route scouting services, fermentation, organic synthesis, chiral technologies, and continuous chemistry using micro reactors.  DSM delivers comprehensive custom manufacturing services to the spectrum of pharmaceutical companies including emerging pharmaceutical companies and large pharmaceutical companies from clinical to commercial manufacturing.  More information: www.dsmpharmachemicals.com

DSM Pharmaceutical Products

DSM Pharmaceutical Products is a global provider of high quality custom contract manufacturing and development services to the pharmaceutical and biopharmaceutical industries. DSM contract manufacturing services include: chemical development, registered intermediates, registered starting materials, active pharmaceutical ingredients (API's), mammalian cell production of monoclonal antibodies and proteins, formulation development, clinical trial manufacturing and finished dose form manufacturing of solids, semi-solids, and scheduled drugs, aseptic liquid and lyophilized products. More information: www.dsmpharmaceuticalproducts.com

DSM - the Life Sciences and Materials Sciences Company

Royal DSM N.V. creates solutions that nourish, protect and improve performance. Its end markets include human and animal nutrition and health, personal care, pharmaceuticals, automotive, coatings and paint, electrical and electronics, life protection and housing. DSM manages its business with a focus on the triple bottom line of economic performance, environmental quality and social responsibility, which it pursues simultaneously and in parallel. DSM has annual net sales of about euro 8 billion and employs some 22,700 people worldwide. The company is headquartered in the Netherlands, with locations on five continents. DSM is listed on Euronext Amsterdam. More information: www.dsm.com

Suggested Articles

After years of having first-line liver cancer market to itself, Bayer’s Nexavar is getting major competition from Roche's Tecentriq.

Most of the recent enthusiasm around AbbVie’s new drugs has centered on Skyrizi and Rinvoq, but elagolix wants a piece of the spotlight, too.

During David Loew's tenure, Sanofi Pasteur bought Protein Sciences, whose recombinant technology is being applied to a COVID-19 vaccine.